Abcuro is a clinical stage biotechnology company developing treatments for autoimmune and cancer indications modulated by cytotoxic T and NK cells that express the inhibitory immune checkpoint receptor KLRG1 (killer cell lectin-like receptor G1). The company is advancing ABC008, a first-in-class anti-KLRG1 antibody designed to deplete cytotoxic T cells that attack healthy muscle tissue in patients with inclusion body myositis (IBM), into clinical studies.

Biotechnology

Abcuro

Alex Martin

Stephanie Amador

Eileen Brennan

Weilee Chen

Zarna Patel

Andrew Marth

Jeff Geary

Jeffrey Luk

Karma Tashi

Chidi Obi

Bill Yates

Daniel Mansuri

Kristin Lurk

Ricky Motschwiller

Raquel Orozco

Donna Byrne

Terry Chaney

Mike Gress

Karen Tubridy

Garry Weems

Hugo Lemessurier

Dave Borbas

Janaki Subramanyam

Dulce Soler-Ferran

LaDonna Hoffer

H. Jeffrey Wilkins, MD

The Management and Directors team at Abcuro oversees strategic decision-making, operations, program management, analytical development, and human resources. This team ensures that the company's clinical advancements, such as the ABC008 anti-KLRG1 antibody, align with overall business objectives and regulatory standards to effectively treat autoimmune and cancer indications.

Management and Directors

Leadership Team

Quality and Regulatory Team

Management and Directors

About

Team members

Other teams at Abcuro

Leadership Team

Quality and Regulatory Team